NCT04513548View on ClinicalTrials.gov

Study of Mechanism of Action of Ligelizumab (QGE031) in Patients With Chronic Urticaria

PHASE1TerminatedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

August 5, 2020

Primary Completion Date

July 19, 2022

Study Completion Date

July 19, 2022

Conditions
Chronic Spontaneous UrticariaCholinergic UrticariaCold Urticaria
Interventions
DRUG

Ligelizumab

One injection every four weeks

DRUG

Placebo

One injection every four weeks

Trial Locations (1)

13353

Novartis Investigative Site, Berlin

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY